A biomanufacturing cleanroom suite with stainless bioreactor vessels

Cell and Gene Therapy Company

Production capacity financed against the equipment, not against earnings the company had not reached yet.

Transaction Size
$3.7MM
Financing Structure
Lease
Term
60 Months
Sector
Healthcare
Equipment
Laboratory and production equipment
Funding Speed
healthcare
The Client

A therapeutics company building its own production capacity

A cell and gene therapy company in Southern California, moving from development into controlled production in its own facility.

The Challenge

Strong backing, real assets, and no EBITDA to show a credit committee

The company had investors, programs and a clear need for cleanroom and production equipment. What it did not have was the trading history a conventional credit process is built to assess. Banks looked for earnings that a company at this stage does not generate by design. The alternative was funding capital equipment out of the equity raised to fund science, which is the most expensive money in the building.

The Solution

Underwritten on the equipment and the backing behind it

Alliance Funding Group structured the facility around the assets and the strength of the company's funding position rather than around historical earnings. Financing the laboratory and production equipment separately from the equity meant the raise stayed committed to programs rather than being consumed by fit-out.

The Outcome

In-house capacity, with the raise left doing what it was raised for

The company brought production capacity in-house on its own timeline, holding processes and intellectual property inside the business rather than at a contract manufacturer. The equity raised for research remained available for research.

Get Started

Ready to become our next success story?

Let's discuss how we can help your business achieve results like these.

Request a Call